欧盟法规
ECHA物质C&L通报上下游产品
silver(I) trifluoromethoxide 3,5-dibromoaniline 6-(3-Bromo-5-trifluoromethoxy-phenyl)-4,4-dimethyl-1,4-dihydrobenzo[d][1,3]-oxazin-2-one 1-(3-bromo-5-(trifluoromethoxy)phenyl)ethanone 1-bromo-3-(tert-butyl)-5-(trifluoromethoxy)benzene 合成工艺路线路线简述
- 合成目标产物 1,3-Dibromo-5-(Trifluoromethoxy)Benzene 主要起始原料 Methanol, 1,1,1-Trifluoro-, Silver(1+) Salt (1:1) And 3,5-Dibromoaniline
- (文献来源)合成步骤主要原料 Methanol, 1,1,1-Trifluoro-, Silver(1+) Salt (1:1) 和 3,5-Dibromoaniline
Silver(I) Trifluoromethoxide,3,5-Dibromophenyldiazonium Tetrafluoroborate 以 乙腈 用作溶剂,化学反应 2.0H,以79%的收率获得1,3-二溴-5-(三氟甲氧基)苯
参考文献:一种芳胺三氟甲氧基化反应的方法
标题:一种芳胺三氟甲氧基化反应的方法
摘要:本发明提供了一种由芳胺化合物合成芳基三氟甲氧基化合物的方法,该方法是将芳胺进行重氮化反应,生成的芳基重氮盐与三氟甲氧基银的乙腈溶剂一锅法反应,得到相应的芳基三氟甲氧基产物,得到的产物产率高,过程简单.
海关参考信息
- 2905110000-甲醇
2908199090-其他酚的卤化衍生物
2908999090-其他酚的硝化衍生物
2918290000-其他含酚基羧酸 - 💡 提示:海关信息按照顺序优先匹配,如需确认的海关信息,请参考相关资料。
- 详情请参考:📖 海关编码查询和海关进出口税则
专利信息
专利号:US-8178559-B2
优先权日:2004-12-30
标 题:Organic compounds
发明人:BREITENSTEIN WERNER; EHARA TAKERU; EHRHARDT CLAUS; GROSCHE PHILIPP; HITOMI YUKO; IWAKI YUKI; KANAZAWA TAKANORI; KONISHI KAZUHIDE; MAIBAUM JUERGEN KLAUS; MASUYA KEIICHI; IWASAKI ATSUKO; OSTERMANN NILS; SUZUKI MASAKI; TOYAO ATSUSHI; YOKOKAWA FUMIAKI
权利人:BREITENSTEIN WERNER; EHARA TAKERU; EHRHARDT CLAUS; GROSCHE PHILIPP; HITOMI YUKO; IWAKI YUKI; KANAZAWA TAKANORI; KONISHI KAZUHIDE; MAIBAUM JUERGEN KLAUS; MASUYA KEIICHI; IWASAKI ATSUKO; OSTERMANN NILS; SUZUKI MASAKI; TOYAO ATSUSHI; YOKOKAWA FUMIAKI; NOVARTIS AG
摘要:3,4-substituted piperidine compounds, these compounds for use in the diagnostic and therapeutic treatment of a warm-blooded animal, especially for the treatment of a disease (=disorder) that depends on activity of renin; the use of a compound of that class for the preparation of a pharmaceutical formulation for the treatment of a disease that depends on activity of renin; the use of a compound of that class in the treatment of a disease that depends on activity of renin; pharmaceutical formulations comprising a 3,4-substituted piperidine compound, and/or a method of treatment comprising administering a 3,4substituted piperidine compound, a method for the manufacture of a 3,4-substituted piperidine compound, and novel intermediates and partial steps for their synthesis are disclosed. The 3,4-disubstituted piperidine compounds have the formula (I), wherein the symbols have the meanings defined in the specification.